Last reviewed · How we verify

NCT05364060: COVID-SME

COVID-19 and Mental Health in Eure

Status unknown Last updated 10 November 2022
What this trial tests

trial testing Questionnaires in COVID-19 Pandemic in 585 participants. Status unknown.

Timeline
13 June 2022
Primary endpoint
13 June 2023
13 June 2023

Quick facts

Lead sponsorCentre Hospitalier Eure-Seine
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment585
Start date13 June 2022
Primary completion13 June 2023
Estimated completion13 June 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Eure-Seine

Who can join

18 and older, any sex, with COVID-19 Pandemic or Psychiatric Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Research Hypothesis: Living conditions during COVID-19, and lockdowns and curfews impact the psychological state of patients (assessed by the degree of depression, positive and negative thoughts, insomnia, state of post-traumatic stress).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Questionnaires

Trials testing the same drug.

Other recruiting trials for COVID-19 Pandemic

Currently open trials in the same condition.

Other Centre Hospitalier Eure-Seine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05364060.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing